Carolyn Taylor Purchases Tonix Pharmaceuticals Shares
Insider Carolyn Taylor acquired 1,415 shares of Tonix Pharmaceuticals on June 12, 2026.
Key Points
- Carolyn Taylor bought 1,415 shares of Tonix Pharmaceuticals for $14,928.25 on June 12, 2026.
- Tonix Pharmaceuticals, trading at $11.35, has a market cap of $183.6 million and a forward P/E of -1.48.
- Several institutions, including BlackRock and Vanguard, have adjusted their positions in Tonix Pharmaceuticals.
On June 12, 2026, insider Carolyn Taylor purchased 1,415 shares of Tonix Pharmaceuticals Holding Corp. (NasdaqGS: TNXP) for a total value of $14,928.25. The shares were bought at an average price of $10.55 each.
Insider Buying and Selling at Tonix Pharmaceuticals Holding Corp.
Recent insider activity at Tonix Pharmaceuticals includes Carolyn Taylor's purchase of 1,415 shares at $10.55 each. On June 9, 2026, CEO Dr. Seth Lederman also bought 5,000 shares at $11.79 per share. Earlier, on June 8, Richard Newcomb Stillwell acquired 5,000 shares at $11.65. In May, Richard Bagger and Richard Newcomb Stillwell both bought 22,700 shares each without a specified price.
Other Institutional Activity in Tonix Pharmaceuticals
Several major institutional investors have recently adjusted their holdings in Tonix Pharmaceuticals. BlackRock, Inc. increased its position by 83,296 shares, now holding 968,177 shares valued at approximately $13.3 million. Vanguard Capital Management LLC initiated a new position, acquiring 518,650 shares worth about $7.1 million. Citadel Advisors LLC and Jones Hill Capital LP both entered new positions with 468,712 shares valued at $6.4 million and 452,116 shares valued at $6.2 million, respectively. Geode Capital Management, LLC added 41,387 shares, totaling 313,291 shares valued at $4.3 million.
Tonix Pharmaceuticals Stock Snapshot
Shares of Tonix Pharmaceuticals are currently trading at $11.35. The company has a market capitalization of approximately $183.6 million. Its forward price-to-earnings ratio is not meaningful as the company is not currently profitable. Tonix has a beta of 1.679, indicating higher volatility compared to the market. The stock's 52-week range is between $10.03 and $69.97, with a 50-day moving average of $12.993 and a 200-day moving average of $17.0676.
Analysts Set New Price Targets
On May 4, 2026, TD Cowen initiated coverage on Tonix Pharmaceuticals with a 'buy' rating and a price target of $22. The stock has a consensus recommendation of 'strong buy' with an average target price of $46.25, based on four analyst opinions.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company based in Berkeley Heights, New Jersey. It focuses on developing and commercializing therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. The company offers products like TONMYA for fibromyalgia and Zembrace SymTouch for acute migraines. It is also working on a range of other treatments, including TNX-102 SL for depression and TNX-801 for smallpox prevention. Founded in 2007, the company is led by CEO Dr. Seth Lederman and employs 142 people.
Bottom Line
Carolyn Taylor's recent purchase of Tonix Pharmaceuticals shares is a notable insider transaction. Investors often watch insider buys closely for potential signals about a company's prospects. While this transaction reflects Taylor's confidence, it's important to remember that insider activity is just one piece of the puzzle. As always, these insights are based on past filings and may not represent current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.